Trial Profile
A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) for Patients With Relapsed/Refractory Aggressive B Cell Lymphomas
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Bendamustine; Rituximab
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 17 Jun 2021 Results (n=56) presented at the 26th Congress of the European Haematology Association.
- 04 Dec 2018 Interim results (n=32) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 07 Mar 2017 Status changed from not yet recruiting to recruiting.